[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2400784C - Produit therapeutique, son application et sa formulation - Google Patents

Produit therapeutique, son application et sa formulation Download PDF

Info

Publication number
CA2400784C
CA2400784C CA002400784A CA2400784A CA2400784C CA 2400784 C CA2400784 C CA 2400784C CA 002400784 A CA002400784 A CA 002400784A CA 2400784 A CA2400784 A CA 2400784A CA 2400784 C CA2400784 C CA 2400784C
Authority
CA
Canada
Prior art keywords
product
dosage form
release
therapeutic agent
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002400784A
Other languages
English (en)
Other versions
CA2400784A1 (fr
Inventor
Edward M. Rudnic
James D. Isbister
Donald J. Treacy, Jr.
Sandra E. Wassink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi Inc
Original Assignee
Advancis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advancis Pharmaceutical Corp filed Critical Advancis Pharmaceutical Corp
Publication of CA2400784A1 publication Critical patent/CA2400784A1/fr
Application granted granted Critical
Publication of CA2400784C publication Critical patent/CA2400784C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un produit thérapeutique comprenant un premier dosage thérapeutique, un deuxième dosage thérapeutique et un troisième dosage thérapeutique, chacun de ces dosages contenant au moins un agent thérapeutique et un support pharmaceutiquement acceptable et ayant des profils de libération différents. Le produit thérapeutique atteint une Cmax en moins de douze heures environ et renferme un agent antibiotique, antifongique, antiviral et antinéoplasique.
CA002400784A 2000-02-24 2001-02-22 Produit therapeutique, son application et sa formulation Expired - Lifetime CA2400784C (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US18454600P 2000-02-24 2000-02-24
US60/184,546 2000-02-24
US68723600A 2000-10-13 2000-10-13
US68722900A 2000-10-13 2000-10-13
US68723500A 2000-10-13 2000-10-13
US68723700A 2000-10-13 2000-10-13
US09/687,235 2000-10-13
US09/687,229 2000-10-13
US09/687,237 2000-10-13
US09/687,236 2000-10-13
PCT/US2001/005758 WO2001062229A1 (fr) 2000-02-24 2001-02-22 Produit therapeutique, son application et sa formulation

Publications (2)

Publication Number Publication Date
CA2400784A1 CA2400784A1 (fr) 2001-08-30
CA2400784C true CA2400784C (fr) 2009-05-19

Family

ID=27539122

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002400784A Expired - Lifetime CA2400784C (fr) 2000-02-24 2001-02-22 Produit therapeutique, son application et sa formulation

Country Status (5)

Country Link
EP (1) EP1257255A4 (fr)
JP (2) JP2003523378A (fr)
AU (1) AU2001239838A1 (fr)
CA (1) CA2400784C (fr)
WO (1) WO2001062229A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AR034813A1 (es) † 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
EP1443910A1 (fr) * 2001-11-02 2004-08-11 Wockhardt Limited Compositions a liberation controlee pour agents antimicrobiens macrolides
WO2003053450A1 (fr) * 2001-12-21 2003-07-03 Biopartners Gmbh Granulat de ribavirine pour la production de comprimes pellicules
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
WO2005009365A2 (fr) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Produit antibiotique, son utilisation et sa formulation
EP1648418A4 (fr) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Produit antibiotique, utilisation et formulation associees
EP1648407A4 (fr) * 2003-07-21 2011-08-31 Middlebrook Pharmaceuticals Inc Produit antibiotique, utilisation et formulation correspondantes
CA2535398C (fr) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotique, utilisation et formulation associees
US7348144B2 (en) * 2003-08-13 2008-03-25 Agilent Technologies, Inc. Methods and system for multi-drug treatment discovery
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
WO2005027877A1 (fr) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotique, son utilisation et sa formulation
EP1701705A4 (fr) * 2003-12-24 2007-08-08 Advancis Pharmaceutical Corp Absorption amelioree de formes de dosage a liberation modifiee
JP5249050B2 (ja) * 2006-01-19 2013-07-31 ダウ グローバル テクノロジーズ エルエルシー エチルセルロースを含む生物活性組成物
CA2635606A1 (fr) * 2006-12-04 2008-06-12 Advancis Pharmaceutical Corporation Produits d'amoxicilline a liberation modifiee
EP2197424A2 (fr) * 2007-10-17 2010-06-23 Pharmathen S.A. Composition pharmaceutique améliorée contenant un agent antiviral et procédé de préparation de celle-ci

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL64009A (en) * 1980-10-31 1984-09-30 Rech Applications Therap Crystalline 1,1-dioxopenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate tosylate hydrates,their production and pharmaceutical compositions containing them
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
JPS61210025A (ja) * 1985-03-14 1986-09-18 Teisan Seiyaku Kk 安定化された抗生物質複合顆粒製剤
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
WO1996010996A1 (fr) * 1993-07-21 1996-04-18 The University Of Kentucky Research Foundation Gelule a plusieurs compartiments assurant une liberation controlee
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system

Also Published As

Publication number Publication date
EP1257255A1 (fr) 2002-11-20
AU2001239838A1 (en) 2001-09-03
JP2012001528A (ja) 2012-01-05
WO2001062229A1 (fr) 2001-08-30
EP1257255A4 (fr) 2008-07-30
JP2003523378A (ja) 2003-08-05
CA2400784A1 (fr) 2001-08-30
JP5377465B2 (ja) 2013-12-25

Similar Documents

Publication Publication Date Title
US6544555B2 (en) Antibiotic product, use and formulation thereof
JP5377465B2 (ja) 治療剤製品、その使用及び製剤形態
US6730320B2 (en) Tetracycline antibiotic product, use and formulation thereof
US20020004070A1 (en) Antineoplastic product, use and formulation thereof
US6669948B2 (en) Antibiotic product, use and formulation thereof
US6667057B2 (en) Levofloxacin antibiotic product, use and formulation thereof
US6663891B2 (en) Erythromyacin antibiotic product, use and formulation thereof
US6667042B2 (en) Fluroquinilone antibiotic product, use and formulation thereof
US7025989B2 (en) Multiple-delayed released antibiotic product, use and formulation thereof
US6663890B2 (en) Metronidazole antibiotic product, use and formulation thereof
US7108859B2 (en) Antineoplastic product, use and formulation thereof
US7105174B2 (en) Multiple-delayed release anti-neoplastic product, use and formulation thereof
US8313775B2 (en) Antibiotic product, use and formulation thereof
US8425936B2 (en) Antibiotic product, use and formulation thereof
US8062672B2 (en) Antibiotic product, use and formulation thereof
AU2006201923B2 (en) Therapeutic product, use and formulation thereof
US20050058708A1 (en) Antibiotic product, use and formulation thereof

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210222